Professor Martin Reck explaining the background for CheckMate 9LA-study and the effect of the combination of nivolumab and ipilimumab + 2 cycles of chemotherapy as first-line treatment of stage IV/recurrent non-small cell lung cancer.

In this MEDtalk Eric J. Small, MD and principal investigator of the SPARTAN study describe what characterizes the group of patients with nonmetastatic castration-resistant prostate cancer?

In this MEDtalk Eric J. Small, MD and principal investigator of the SPARTAN study, explains the clinical benefits from early treatment of patients with nonmetastatic castration-resistant prostate cancer

In this MEDtalk, Eric J. Small talks about to which extent patients with non-metastatic castration-resistant prostate cancer achieve metastasis-free survival and whether it is possible to delay the time until chemotherapy, as well as the impact of treatment on survival.

Eric J. Small, MD and principal investigator of the SPARTAN study explains the background and study design of the SPARTAN study, where the efficiency and safety of apalutamide for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) was investigated.

The COVID-19 pandemic has changed the format of this year’s ASCO Annual Meeting. The conference ran from 29 – 31 May under the theme "Unite and Conquer: Accelerating Progress Together."

#Senaste Tidskrift

Non-Melanoma Skin Cancer

Nr. 1 • april 2020
Årgang 1
  • Causes
  • Treatments
  • News

Tweets by ASCO